Pancreatic cancer is deadly and difficult to treat. A new pill could change that
Summary
A new drug called daraxonrasib shows promise in treating pancreatic cancer by targeting a gene mutation common in this disease. Early trial results suggest that patients taking the drug lived nearly twice as long as those receiving standard chemotherapy.Key Facts
- Daraxonrasib is a pill developed by Revolution Medicines that targets the KRAS gene mutation.
- KRAS mutations occur in over 90% of common pancreatic cancer cases.
- The drug belongs to a class called RAS inhibitors.
- Pancreatic cancer is very deadly, with a 3% five-year survival rate after it spreads.
- Most patients are diagnosed after the cancer has advanced.
- In early trials, patients taking daraxonrasib survived about 13.2 months on average.
- This compares to 6.7 months for patients on standard chemotherapy alone.
- Daraxonrasib was used after initial treatments, as a "second line" therapy.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.